当前位置: X-MOL首页 › SCI期刊查询及投稿分析系统 › Therapeutic Advances in Musculoskeletal Disease杂志
Therapeutic Advances in Musculoskeletal Disease
基本信息
期刊名称 | Therapeutic Advances in Musculoskeletal Disease THER ADV MUSCULOSKEL |
---|---|
期刊ISSN | 1759-720X |
期刊官方网站 | https://journals.sagepub.com/home/tab |
是否OA | Yes |
出版商 | SAGE Publications Inc. |
出版周期 | |
文章处理费 | 登录后查看 |
始发年份 | |
年文章数 | 48 |
影响因子 | 3.4(2023) scijournal影响因子 greensci影响因子 |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学2区 | RHEUMATOLOGY 风湿病学2区 | 否 | 是 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 6.8 | 1.061 | 1.106 |
Medicine Orthopedics and Sports Medicine |
31/321 | 90% |
|||
Medicine Rheumatology |
17/73 | 77% |
补充信息
自引率 | 2.9% |
---|---|
H-index | 27 |
SCI收录状况 |
Science Citation Index Expanded |
官方审稿时间 | 登录后查看 |
网友分享审稿时间 | 数据统计中,敬请期待。 |
接受率 | 登录后查看 |
PubMed Central (PMC) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1759-720X%5BISSN%5D |
投稿指南
期刊投稿网址 | https://mc.manuscriptcentral.com/tamd |
---|---|
收稿范围 | Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of osteoporosis and rheumatic diseases such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis and other related musculoskeletal diseases. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in rheumatology, osteoporosis and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be follows (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; online publication is usually within 3 weeks of Acceptance. |
收录体裁 | |
投稿指南 | https://journals.sagepub.com/author-instructions/tab |
投稿模板 | |
参考文献格式 | |
编辑信息 |
我要分享 (欢迎您来完善期刊的资料,分享您的实际投稿经验)